Preview

User

Not a user? Register with this site Forgot your password?

Medical alphabet

Advanced search
Open Access Open Access  Restricted Access Subscription or Fee Access

Atezolizumab and nab-paclitaxel for advanced triple-negative breast cancer in real-world practice

https://doi.org/10.33667/2078-5631-2025-11-17-24

Abstract

Introduction. Advances in molecular biology and biotechnology have enhanced the understanding of triple-negative breast cancer (TNBC) biology and facilitated the identification of patient subgroups that may potentially benefit from novel therapeutic approaches.

Objective. The aim of this study is to evaluate the efficacy of the combination of atezolizumab and nab-paclitaxel in patients with locallyadvanced/metastatic TNBC in real-world clinical practice in the Russian Federation.

Methods. This retrospective multicenter study included 65 patients with metastatic TNBC who received the atezolizumab and nab-paclitaxel in the second line of treatment and patients with early progression following neoadjuvant/adjuvant chemotherapy (≤12 months, primary resistance population) from October 2019 to September 2023 in routine clinical practice.

Results. At the median follow-up of 11.5 months the median progression-free survival (mPFS) was 11.43 months (95 % CI, 6.59–16.28) in the ITT population. There was only factor associated with worsened mPFS – recurrence-free interval of ≤12 months following anthracycline/taxane-based neoadjuvant/adjuvant chemotherapy. mPFS was 15.8 months for primary metastatic or anthracycline/taxane-sensitive TNBC vs. 6.4 months for primary resistance population (OR 0.52, 95 % CI 0.54–0.97; p=0.03). A trend towards improved PFS was observed in the BRCA1/2 wt subgroup and patients with objective response. The mPFS for BRCA1/2 wt patients was 13.9 months vs. 5.6 months for BRCA1/2 mut patients (p=0.14). mPFS in patients with an objective response was 21.9 months vs 13.9 months in those without an objective response (p=0.63).

Conclusions. This analysis represents the first multicenter study evaluating the efficacy of the combination of atezolizumab and nab-paclitaxel in real-world clinical practice in Russian population. The combination allows for an objective response rate of 20 % and mPFS of 11.43 months for patients as in the second line of treatment as with primary resistance.

About the Authors

I. P. Ganshina
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation

Ganshina Inna P. - PhD Med, leading researcher at Dept of Antitumor Drug Therapy No.1 Dept of Drug Treatment.

Moscow


E. V. Artamonova
N.N. Blokhin National Medical Research Center of Oncology; Pirogov Russian National Research Medical University; M.F. Vladimirsky Moscow Regional Research and Clinical Institute
Russian Federation

Artamonova Elena V. - DM Sci (habil.), head of Dept of Drug Therapy (Chemotherapy No. 1) N. N. Blokhin National Medical Research Center of Oncology, professor at Dept of Oncology and Radiation Therapy Pirogov Russian National Research Medical University, head of Dept of Oncology and Thoracic Surgery M. F. Vladimirsky Moscow Regional Research and Clinical Institute.

Moscow


Yа. A. Zhulikov
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation

Zhulikov Yaroslav A. - oncologist at Dept of Antitumor Drug Therapy No. 1, Dept of Drug Treatment.

Moscow


M. V. Koroleva
Pirogov Russian National Research Medical University
Russian Federation

Koroleva Maria V. - 6th year student.

Moscow


L. G. Zhukova
A.S. Loginov Moscow Clinical Scientific and Practical Center
Russian Federation

Zhukova Liudmila G. - DM Sci (habil.), corr. memb. RAS, deputy director for Oncology.

Moscow


D. A. Filonenko
A.S. Loginov Moscow Clinical Scientific and Practical Center
Russian Federation

Filonenko Daria A. - PhD Med, head of Outpatient Chemotherapy Dept.

Moscow


M. V. Sukhova
A.S. Loginov Moscow Clinical Scientific and Practical Center
Russian Federation

Sukhova Margarita V. – oncologist.

Moscow


E. P. Anokhina
Regional Clinical Oncology Dispensary
Russian Federation

Anokhina Ekaterina P. - oncologist at Day Hospital Chemotherapist.

Ulyanovsk


I. G. Aseeva
Clinical Oncology Dispensary No. 1
Russian Federation

Aseeva Irina I. - oncologist at Dept of Antitumor Drug Therapy № 1.

Krasnodar


S. V. Averyanova
Regional Clinical Oncology Dispensary
Russian Federation

Averyanova Svetlana V. - PhD Med, deputy Chief Physician for Medical Affairs.

Saratov


S. A. Bolshakova
Russian Scientific Center for Radiology and Surgical Technologies
Russian Federation

Bolshakova Svetlana A. - PhD Med, senior researcher at Laboratory of Radiation Therapy and Integrated Methods of Treatment of Oncological Disease.

Moscow


V. V. Vysotskaya
Research Institute of Oncology – Branch of the Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation

Visotskaya Vitalina V. - oncologist, researcher at Chemotherapy Dept.

Tomsk


A. E. Vasiliev
Orenburg Regional Clinical Oncology Dispensary
Russian Federation

Vasiliev Alexey E., chief chemotherapist of Orenburg Region, head of Dept of Antitumor Drug Therapy.

Orenburg


M. V. Volkonsky
Moscow City Oncology Hospital No. 62
Russian Federation

Volkonskiy Mikhail V. - head of Dept of Antitumor Drug Therapy.

Moscow


D. V. Voronin
Clinical Oncology Dispensary No. 1
Russian Federation

Voronin Dmitriy V. - oncologist at Day Hospital for Antitumor Drug Therapy and Chemotherapy.

Krasnodar


D. L. Valkin
Moscow Multidisciplinary Clinical Center «Kommunarka»
Russian Federation

Valkin Dmitriy L. - head of Oncology Dept No. 2.

Moscow


V. E. Goldberg
Research Institute of Oncology – Branch of the Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation

Goldberg Viktor E., head of the Chemotherapy Dept.

Tomsk


E. A. Dudnikova
Research Institute of Oncology – Branch of the Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation

Dudnikova Ekaterina A. - oncologist, researcher at Chemotherapy Dept.

Tomsk


G. A. Dashyan
N.I. Pirogov Clinic of High Medical Technologies, St. Petersburg State University
Russian Federation

Dashyan Garik A. - DM Sci (habil.), associate professor, head of Oncology Dept No. 1.

St. Petersburg


O. V. Zharkova
Kamchatka Regional Oncology Dispensary
Russian Federation

Zharkova Olga V. - PhD Med, deputy chief physician.

Petropavlovsk-Kamchatsky


R. A. Zukov
Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky; Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation

Zukov Ruslan A. - DM Sci (habil.), head physician Krasnoyarsk Regional Clinical Oncology Dispensary named after A. I. Kryzhanovsky, professor, head of Dept of Oncology and Radiotherapy Prof. V. F. Voino-Yasenetsky Krasnoyarsk State Medical University.

Krasnoyarsk


A. M. Ivanov
Center for Immune and Targeted Therapy
Russian Federation

Ivanov Alexey M. - head of Chemotherapy Dept.

Moscow


E. E. Kiseleva
Nizhny Novgorod Regional Clinical Oncology Dispensary
Russian Federation

Kiseleva Elena E. - oncologist, 4th Oncology Dept of Antitumor Drug Therapy (Day Hospital).

Nizhny Novgorod


Yu. V. Kostalanova
Samara Regional Clinical Oncology Dispensary
Russian Federation

Kostalanova Yulia V. - PhD Med, head of h Dept of Chemotherapy No. 2.

Samara


O. I. Kaganov
Samara Regional Clinical Oncology Dispensary
Russian Federation

Kaganov Oleg I. - DM Sci (habil.), head of Dept of Oncology.

Samara


D. G. Lazareva
Altai Regional Oncology Dispensary; Altai State Medical University»
Russian Federation

Lazareva Darya G. - PhD Med, associate professor at Dept of Oncology and Radiation Therapy with a Course in Additional Professional Education35, head of Dept of Antitumor Drug Therapy No. 1.

Barnaul


O. A. Lyubimova
Perm Regional Oncology Dispensary
Russian Federation

Lyubimova Olga A. - oncologist, head of Dept of Breast and Skin Cancer.

Perm


I. V. Myslevtsev
S.P. Botkin Moscow Multidisciplinary Clinical Center
Russian Federation

Myslevtsev Igory V. - head of Dept of Chemotherapy.

Moscow


V. V. Mikhalyuk
Nizhnevartovsk Oncology Dispensary, Khanty-Mansi Autonomous Okrug – Yugra
Russian Federation

Mikhalyuk Victoria V. - oncologist, head of Dept of Antitumor Drug Therapy.

Nizhnevartovsk


H. M. Mezhidova
Republican Oncology Dispensary
Russian Federation

Mezhidova Khalimat M. - oncologist at Dept of Chemotherapy.

Grozny


M. R. Mukhitova
Republican Clinical Oncology Dispensary named after Professor M.Z. Sigal
Russian Federation

Mukhitova Milyausha R. - head of Dept of Day Hospital.

Kazan


K. V. Menshikov
Republican Clinical Oncology Dispensary; Bashkir State Medical Universitya
Russian Federation

Menshikov Konstantin V. - PhD Med, associate professor at Dept of Oncology and Clinical Morphology Bashkir State Medical Universitya, oncologist at Chemotherapy Dept Republican Clinical Oncology Dispensary.

Ufa


A. E. Orlov
Samara Regional Clinical Oncology Dispensary
Russian Federation

Orlov Andrey E. - DM Sci (habil.), professor, chief physician.

Samara


S. A. Orlova
Republican Clinical Oncology Dispensary
Russian Federation

Orlova Svetlana A. - head of Dept of Chemotherapy.

Cheboksary


N. O. Popova
Research Institute of Oncology – Branch of the Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation

Popova Natalia O. - oncologist, senior researcher at Chemotherapy Dept.

Tomsk


E. V. Peganova
Regional Clinical Oncology Hospital
Russian Federation

Peganova Ekaterina V. - head of Dept of Day Hospital.

Yaroslavl


A. P. Pecheny
Orel Oncology Dispensary
Russian Federation

Petchoniy Alexandr P. - PhD Med, oncologist at Dept of Antitumor Drug Therapy.

Orel


N. M. Rats
Clinical Oncology Dispensary
Russian Federation

Rats Natalia M. - oncologist at Dept of Antitumor Drug Therapy (Chemotherapy).

Omsk


E. I. Simolina
Research Institute of Oncology – Branch of the Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation

Simolina Elena I., oncologist, researcher at Chemotherapy Dep.

Tomsk


A. V. Sultanbaev
Republican Clinical Oncology Dispensary
Russian Federation

Sultanbaev Alexander V. - PhD Med, head of Dept of Anticancer Drug Therapy.

Ufa


Yu. E. Stepura
JSC K+31 Clinic
Russian Federation

Stepura Yulia E. - head of Dept of Antitumor Drug Therapy.

Moscow


M. V. Sukhova
A.S. Loginov Moscow Clinical Scientific and Practical Center Sakhalin Regional Oncology Dispensary
Russian Federation

Sukhova Margarita V. - oncologist at Chemotherapy Dept.

Moscow


T. H. Temirsultanova
Republican Oncology Dispensary
Russian Federation

Temirsultanova Toita H. - head of Dept of Chemotherapy.

Grozny


I. S. Usoltseva
Sakhalin Regional Oncology Dispensary
Russian Federation

Usoltseva Inessa S., oncologist at Day Hospital of the Antitumor Drug Therapy Dept, assistant at Dept of Continuing Professional Education.

Yuzhno-Sakhalinsk


O. N. Shirokova
Sverdlovsk Regional Oncology Dispensary
Russian Federation

Shirokova Oksana N. - head of Dept of Antitumor Drug Therapy No. 1.

Yekaterinburg


V. A. Shatalova
Research Institute of Oncology – Branch of the Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation

Shatalova Vasilisa A. - PhD Med, oncologist at Dept of Chemotherapy.

Tomsk


M. V. Shaidorov
Tolyatti City Clinical Hospital No. 5
Russian Federation

Shaydorov Mikhail V. - PhD Med, head of Dept of Chemotherapy.

Tolyatti


References

1. Dent R., Trudeau M., Pritchard K. I., Hanna W. M., Kahn H. K., Sawka C. A., Lickley L. A., Rawlinson E., Sun P., Narod S. A. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res. 2007; 3: 4429-4434. https://doi.org/10.1158/1078-0432.CCR-06-3045

2. Lin N. U. et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012; 118 (22): 5463-5472.

3. Sabatier R. et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015; 6 (7): 5449.

4. Khoroshilov M. V., Kovalenko E. I., Artamonova E. V., Zabotina T. N., Stilidi I. S., Zhulikov Ya. A. Subpopulation composition of tumor-infiltrating lymphocytes in early and locally advanced triple-negative breast cancer and its impact on the effectiveness of neoadjuvant chemotherapy. Malignant tumors. 2023; 13 (4): 28–36. (In Russ.).

5. Mittendorf E. A., Philips A. V., Meric-Bernstam F., Qiao N., Wu Y., Harrington S., Su X., Wang Y., Gonzalez-Angulo A.M., Akcakanat A. et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res. 2014; 2: 361–370. DOI: 10.1158/2326-6066.CIR-13-0127

6. Schmid P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New England Journal of Medicine. 2018; 379 (22): 2108–2121.

7. Schmid P, Cruz C, Braiteh FS, Eder JP, Tolaney S, Kuter I, Nanda R, Chung C, Cassier P, Delord JP, Gordon M, Li Y, Liu B, O’Hear C, Fasso M, Molinero L, Emens LA. Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. AACR Annual Meeting 2017.

8. Schmid P. et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The lancet oncology. 2020; 21 (1): 44–59.

9. Emens L. A., Adams S., Barrios C. H., Diéras V., Iwata H., Loi S., Schmid P. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Annals of Oncology. 2021; 32 (8): 983–993. DOI: 10.1016/j.annonc.2021.05.355

10. Badve S. S. et al. Determining PD-L1 status in patients with triple-negative breast cancer: lessons learned from IMpassion130. JNCI: Journal of the National Cancer Institute. 2022; 114 (5): 664–675.

11. Franzoi M. A., de Azambuja E. Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials-how to explain different results? ESMO open. 2020; 5 (6): e001112. https://doi.org/10.1136/esmoopen-2020-001112

12. Miles DW, Gligorov J, André F. et al. Primary results from IMpassion 131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC)± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2020; 31 (Suppl. 4): S 1142–215.J.


Review

For citations:

Ganshina I.P., Artamonova E.V., Zhulikov Y.A., Koroleva M.V., Zhukova L.G., Filonenko D.A., Sukhova M.V., Anokhina E.P., Aseeva I.G., Averyanova S.V., Bolshakova S.A., Vysotskaya V.V., Vasiliev A.E., Volkonsky M.V., Voronin D.V., Valkin D.L., Goldberg V.E., Dudnikova E.A., Dashyan G.A., Zharkova O.V., Zukov R.A., Ivanov A.M., Kiseleva E.E., Kostalanova Yu.V., Kaganov O.I., Lazareva D.G., Lyubimova O.A., Myslevtsev I.V., Mikhalyuk V.V., Mezhidova H.M., Mukhitova M.R., Menshikov K.V., Orlov A.E., Orlova S.A., Popova N.O., Peganova E.V., Pecheny A.P., Rats N.M., Simolina E.I., Sultanbaev A.V., Stepura Yu.E., Sukhova M.V., Temirsultanova T.H., Usoltseva I.S., Shirokova O.N., Shatalova V.A., Shaidorov M.V. Atezolizumab and nab-paclitaxel for advanced triple-negative breast cancer in real-world practice. Medical alphabet. 2025;(11):17-24. (In Russ.) https://doi.org/10.33667/2078-5631-2025-11-17-24

Views: 28


ISSN 2078-5631 (Print)
ISSN 2949-2807 (Online)

LLC "Alfmed"
129515, Moscow, P.O. BOX 94, Ak. Koroleva st.,13\1
tel.: +7 (495) 616-48-00
e-mail: medalfavit@mail.ru

Processing of personal data
supported by NEICON (Elpub lab)